Persons Reported to be living with HIV infection and with AIDS reported

Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 5,014 3,142 32 17 5,046 3,159 8,156 49 8,205
2001 5,279 3,410 32 17 5,311 3,427 8,889 49 8,738
2002 5,820 3,641 42 19 5,862 3,660 9,461 61 9,522
                   


 

HIV Infection Cases  from areas with confidential HIV infection reporting

Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 498 5,222 39 5,261
2001 491 5,505 41 5,546
2002 522 5,820 42 5,862
         

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States

Year Males Females
  HIV AIDS HIV AIDS
2000 309 366 189 113
2001 297 327 192 109
         


 

Pediatric AIDS cases reported

Year
2000 4
2001 2
2002 19
   

 

Alabama: Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 7,135
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 7,059
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 76

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2000

  AL USA
Men 5,607 680,909
Women 1,196 146,298
Total 6,803 827,208

 

Alabama: New AIDS Cases

New AIDS Cases, Reported through 2002 432
New Adult/Adolescent AIDS Cases, Reported in 2001 436
New AIDS Cases in Children <13, Reported through December 2001 2

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001

  AL USA
Men 327 31,901
Women 109 11,082
Total 436 42,983

 

Alabama: Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 3,660
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 3,641
Estimated Number of Children Living with AIDS at the End of 2002 19
HIV Infection Cases Reported in 2001. 522

 

Total Deaths Reported through 2000, due to AIDS = 3,380
HIV Reporting Requirements ?   Yes, Name based reporting.
 
HIV Testing Options?  Confidential testing only
Definitions:
Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?
 
Voluntary HIV testing; no specific law. State follows CDC guidelines; No specific law or language on testing for mothers and newborns.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration?
NO

Definitions:
1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 

Sterile Syringe Exchange Programs?  No

Notes:
U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  Yes, Must stress abstinence and cover contraception
 
Minors' Right to Consent to HIV/STD Services?  Yes, Minor must be at least 12 years of age. State explicitly classifies HIV/AIDS as an STD or infectious disease, for which minors may consent to testing and treatment. Physician may notify parents.
 
 
Total Ryan White Funding, FY2000   $1,121,741  FY2002  $18,231,999
 

CDC HIV Prevention Funding for States
 FY2001
$2,311,365

FY2003   $2,357,253

 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation

Total ADAP Clients Served, June 2002  
  AL
#
US
#
   919 80,035

 
ADAP Clients Served by Sex, June 2002  
  AL
#
AL
%
US
#
US
%
  Male 709 77 62,034 78
  Female 210 23 16,702 21
  Total 919 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  AL
#
AL
%
US
#
US
%
  White 361 39 29,426 37
  Black 541 59 26,245 33
  Hispanic 10 1 19,883 25
  Asian/Pacific Islander 2 0 795 1
  American Indian/Alaskan Native 2 0 795 1
  Other 3 0 795 1
  Total 919 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  AL
#
AL
%
US
#
US
%
  <13 years old 0 0 795 1
  13-19 years old 9 1 0 1 0 1
  20-44 years old 739 80 50,105 63
  >44 years old 150 16 27,836 35
  Total 919 98 79,531 100

 
ADAP Clients Served by Income, June 2002
   
  AL
#
AL
%
US
#
US
%
  <100% FPL 524 57 38,175 48
  101-200% FPL 358 39 26,245 33
  201-300% FPL 28 3 8,748 11
  301-400% FPL 5 1 3,181 4
  >400% FPL 5 1 1,591 2
  Total 919 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  AL
#
AL
%
US
#
US
%
  Medicaid 0 0 0 10
  Medicare 0 0 0 6
  Private 0 0 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  AL
$
US
$
   9,921,845 878,610,754

 
National ADAP Budget by Source, FY 2002  
  AL
$
AL
%
US
$
US
%
  ADAP Earmark 5,822,611 59 619,830,000 71
  Title II Base 725,854 7 28,886,192 3
  State 2,500,000 25 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 873,380 9 19,170,000 2
  Total 9,921,845 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  AL
$
US
$
   870,116 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  AL
$
AL
%
US
$
US
%
  Nucleoside Reverse Transcriptase Inhibitors 461,706 53 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 112,458 13 7,940,575 12
  Protease Inhibitors 232,358 27 16,433,502 25
  Opportunistic Infections/Other 63,594 7 9,015,329 14
  Total 870,116 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  AL
#
US
#
   3,526 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  AL
#
AL
%
US
#
US
%
  Nucleoside Reverse Transcriptase Inhibitors 1,659 47 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 467 13 23,933 10
  Protease Inhibitors 627 18 33,813 15
  Opportunistic Infections/Other 773 22 87,746 38
  Total 3,526 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  AL
$
US
$
   84,000 2 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  AL
#
US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 6 NA
  Other Medications Covered 2 NA
  Total 26 NA

 
ADAP Emergency Cost Containment Measures, February 2003  
  AL
 
US
 
  Has ADAP Emergency Cost Containment Measures in Place Yes 16 Yes
  Notes Capped enrollment.